Guilin Sanjin Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 14.80%

Guilin Sanjin Pharmaceutical Co Ltd (002275) has an Asset Resilience Ratio of 14.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002275 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥636.30 Million

≈ $93.11 Million USD Cash + Short-term Investments

Total Assets

CN¥4.30 Billion

≈ $629.19 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2010–2024)

This chart shows how Guilin Sanjin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Guilin Sanjin Pharmaceutical Co Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Guilin Sanjin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guilin Sanjin Pharmaceutical Co Ltd market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥636.30 Million	14.8%
Total Liquid Assets	CN¥636.30 Million	14.80%

Asset Resilience Insights

Moderate Liquidity: Guilin Sanjin Pharmaceutical Co Ltd has 14.80% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Guilin Sanjin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guilin Sanjin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Guilin Sanjin Pharmaceutical Co Ltd (2010–2024)

The table below shows the annual Asset Resilience Ratio data for Guilin Sanjin Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	14.79%	CN¥626.15 Million ≈ $91.62 Million	CN¥4.23 Billion ≈ $619.31 Million	+7.05pp
2023-12-31	7.74%	CN¥304.69 Million ≈ $44.59 Million	CN¥3.94 Billion ≈ $575.97 Million	+3.67pp
2022-12-31	4.07%	CN¥161.24 Million ≈ $23.59 Million	CN¥3.96 Billion ≈ $580.19 Million	-1.35pp
2021-12-31	5.41%	CN¥221.77 Million ≈ $32.45 Million	CN¥4.10 Billion ≈ $599.35 Million	-3.74pp
2020-12-31	9.15%	CN¥355.34 Million ≈ $52.00 Million	CN¥3.88 Billion ≈ $568.10 Million	+7.18pp
2019-12-31	1.98%	CN¥67.50 Million ≈ $9.88 Million	CN¥3.42 Billion ≈ $499.81 Million	+1.98pp
2018-12-31	0.00%	CN¥1.27K ≈ $186.02	CN¥3.41 Billion ≈ $498.42 Million	-11.29pp
2017-12-31	11.29%	CN¥364.60 Million ≈ $53.35 Million	CN¥3.23 Billion ≈ $472.59 Million	+3.95pp
2016-12-31	7.34%	CN¥210.66 Million ≈ $30.83 Million	CN¥2.87 Billion ≈ $419.95 Million	+3.51pp
2015-12-31	3.83%	CN¥105.60 Million ≈ $15.45 Million	CN¥2.76 Billion ≈ $403.83 Million	-5.15pp
2014-12-31	8.98%	CN¥250.00 Million ≈ $36.58 Million	CN¥2.78 Billion ≈ $407.33 Million	+8.80pp
2010-12-31	0.18%	CN¥3.60 Million ≈ $527.15K	CN¥1.98 Billion ≈ $289.92 Million	--

pp = percentage points

About Guilin Sanjin Pharmaceutical Co Ltd

SHE:002275 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.07 Billion

CN¥7.29 Billion CNY

Market Cap Rank

#8819 Global

#2211 in China

Share Price

CN¥12.40

Change (1 day)

-1.82%

52-Week Range

CN¥12.40 - CN¥17.38

All Time High

CN¥19.61